Literature DB >> 1571913

Rectal carcinoma. Long-term experience with moderately high-dose preoperative radiation and low anterior resection.

H D Kerman1, S H Roberson, T S Bloom, H C Heron, T E Yaeger, D L Meese, A H Ritter, J T Tolland, A E Spangler.   

Abstract

This report updated an analysis of a 14-year experience of moderately high-dose (4500 to 5000 cGy) preoperative radiation as an adjuvant to low anterior resection of 95 cases of adenocarcinoma of the rectum. The treatment was well tolerated without treatment-related mortality and with a low incidence (5.2%) of severe complications. The local recurrence rate was 4.2%, and distant failure rate was 10.5%. At 5 years, the actuarial survival rate was 66% and the disease-free survival rate was 64%. At 10 years, the actuarial survival rate and disease-free survival rate were 52%. The authors concluded that moderately high-dose (4500 to 5000 cGy) neoadjuvant radiation in clinically resectable adenocarcinoma of the rectum in which one segment of the anastomosis was in the preoperative radiation field is a safe, effective adjuvant to low anterior resection and that it offered patients excellent local control, long-term survival, and sphincter preservation. Results could be enhanced by chemotherapy, and the authors urged well-designed prospective randomized multicenter trials to determine the most appropriate drugs, dosage, and sequencing of co-adjuvant preoperative radiation therapy and chemotherapy with surgery.

Entities:  

Mesh:

Year:  1992        PMID: 1571913     DOI: 10.1002/1097-0142(19920601)69:11<2813::aid-cncr2820691129>3.0.co;2-w

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  4 in total

1.  The long-term effect of adjuvant postoperative chemoradiotherapy for rectal carcinoma on bowel function.

Authors:  C F Kollmorgen; A P Meagher; B G Wolff; J H Pemberton; J A Martenson; D M Illstrup
Journal:  Ann Surg       Date:  1994-11       Impact factor: 12.969

2.  Prognostic value of Smac expression in rectal cancer patients treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Jinming Yu; Renben Wang; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Med Oncol       Date:  2011-01-25       Impact factor: 3.064

3.  Predictive value of Smac, VEGF and Ki-67 in rectal cancer treated with neoadjuvant therapy.

Authors:  Hongjiang Yan; Renben Wang; Jinming Yu; Shumei Jiang; Kunli Zhu; Dianbin Mu; Zhongfa Xu
Journal:  Oncol Lett       Date:  2010-07-01       Impact factor: 2.967

4.  Influence of anemia on tumor response to preoperative chemoradiotherapy for locally advanced rectal cancer.

Authors:  Seong Dae Lee; Ji Won Park; Kui Seon Park; Seok-Byung Lim; Hee Jin Chang; Dae Yong Kim; Seung-Yong Jeong; Hyo Seong Choi; Jae Hwan Oh
Journal:  Int J Colorectal Dis       Date:  2009-07-07       Impact factor: 2.571

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.